Nifedipine

Introduction Overview

Generic Name

Nifedipine

Brand Name

Adalat CC, Afeditab CR, Nifediac CC, Nifedical XL, Procardia, Procardia XL, Adalat

Dosage Form

Extended-release tablet, Immediate-release tablet, Capsules

Drug Class

Calcium channel blockers

Pharmacokinetics

Absorption: Nifedipine is well absorbed orally with peak plasma concentrations achieved within 30 minutes for immediate-release formulations and 6-12 hours for extended-release forms. Its bioavailability is reduced due to significant first-pass metabolism in the liver. Food intake may delay absorption of extended-release formulations but does not reduce overall bioavailability. Clinical implications of this absorption profile mean that nifedipine's onset and duration of action vary depending on the formulation, requiring careful dose timing and adjustment to optimize therapeutic efficacy and minimize side effects.

Distribution: Nifedipine exhibits a large volume of distribution (~21 L/kg), indicating extensive tissue binding, particularly in cardiac and vascular smooth muscle. It is highly lipophilic, readily crossing cell membranes and distributing into adipose tissue. Approximately 92-97% of circulating nifedipine is bound to plasma proteins, primarily albumin. This extensive distribution allows effective vasodilation of peripheral arteries but also affects drug clearance. Tissue distribution impacts drug interactions and dosing in specific populations such as those with altered plasma proteins.

Metabolism: Nifedipine undergoes extensive hepatic metabolism, primarily by cytochrome P450 3A4 (CYP3A4) enzymes, to inactive metabolites that are excreted renally. This metabolic pathway is susceptible to induction or inhibition by other drugs, impacting nifedipine plasma levels and efficacy. Individual variability in CYP3A4 activity contributes to differential patient responses. Notably, coadministration with CYP3A4 inhibitors like ketoconazole or erythromycin can increase nifedipine levels, raising the risk of hypotension and side effects.

Elimination: The elimination half-life of nifedipine varies with formulation, averaging about 2 hours for immediate-release and up to 8 hours for extended-release tablets. It is primarily eliminated by renal excretion of metabolites, with less than 1% excreted unchanged in urine. Hepatic clearance is the main route of elimination; thus, hepatic impairment can prolong drug half-life and increase systemic exposure. The steady-state is typically achieved within a few days of consistent dosing. Understanding elimination kinetics is crucial for dose adjustments in elderly and those with hepatic dysfunction.

Dosage Forms

Available Dosage Forms:
- Extended-release tablets: 30 mg, 60 mg, 90 mg
- Immediate-release tablets: 10 mg, 20 mg
- Capsules (immediate-release): 10 mg, 20 mg
- Combination of formulations tailored for sustained blood pressure control and angina management

Dosages for Adults and Adolescents:
- Hypertension and chronic stable angina: Initial dose typically 30 mg once daily extended-release; may be adjusted based on response to 60 mg daily; maximum dose up to 90 mg daily
- Immediate-release tablets used for acute angina attacks, typically 10 mg three times daily, but less commonly due to side effect profile
- Dose titration recommended when initiating therapy or switching formulations, with monitoring for hypotension and tolerance

Specific Patient Populations:
- In patients with hepatic impairment, lower doses or extended dosing intervals recommended due to decreased metabolism
- Elderly patients may require cautious dose escalation to avoid excessive hypotension
- Limited data in pediatric populations; use generally avoided or carefully monitored
- Lactose content in some extended-release formulations necessitates caution in patients with lactose intolerance
- During pregnancy, use only if potential benefit justifies risk; safety data limited

Clinical Guidelines:
- Extended-release formulations preferred for chronic therapy due to improved compliance and more stable plasma concentrations
- Immediate-release forms used cautiously due to higher incidence of reflex tachycardia and hypotension
- Dosage adjustments based on blood pressure response, side effects, and clinical scenario

Mechanism Of Action

Nifedipine acts primarily as a dihydropyridine calcium channel blocker, selectively inhibiting L-type voltage-gated calcium channels on vascular smooth muscle cells. By blocking calcium influx, nifedipine reduces intracellular calcium concentration, leading to smooth muscle relaxation and vasodilation predominantly in the arterial system. This vasodilation decreases peripheral vascular resistance and thus lowers blood pressure, alleviating the workload on the heart.

At the molecular level, nifedipine binds to specific sites on the alpha-1 subunit of the L-type calcium channels, stabilizing the inactive conformation of the channel and preventing calcium entry during membrane depolarization. This selective action primarily targets vascular rather than cardiac muscle, which explains the limited direct effect on myocardial contractility. Additionally, the decrease in systemic vascular resistance improves coronary artery blood flow, benefiting patients with angina pectoris.

Biochemically, nifedipine's blockade of calcium channels interrupts excitation-contraction coupling in smooth muscle cells. This diminishes actin-myosin interactions necessary for contraction, resulting in vasodilation. The reduction in afterload reduces myocardial oxygen demand, crucial in angina therapy. Moreover, nifedipine's effects on coronary arteries improve oxygen supply to ischemic myocardium.

Clinically, nifedipine is used to manage hypertension and angina due to these vasodilatory effects. Compared to non-dihydropyridine calcium channel blockers like verapamil, nifedipine has minimal negative inotropic or chronotropic effects, making it preferable in patients where cardiac conduction effects are undesirable. Research demonstrates nifedipine's efficacy in reducing blood pressure, improving exercise tolerance in angina, and its role in certain hypertensive emergencies when given intravenously in hospital settings.

Pharmacological Actions

Inhibition of L-type calcium channels in vascular smooth muscle leading to arterial vasodilation.
Reduction of peripheral vascular resistance and systemic blood pressure lowering.
Coronary artery dilation increasing myocardial oxygen delivery.
Decrease in myocardial oxygen demand by reducing afterload.
Minimal direct negative inotropic effect compared to non-dihydropyridine calcium channel blockers.
Decreased vascular smooth muscle tone improving angina symptoms.
Potential reflex sympathetic activation causing tachycardia with immediate-release formulations.
Renal vasodilation possibly enhancing renal blood flow.
Suppression of coronary artery spasm.
Improvement of endothelial function through vasodilatory mechanisms.

Therapeutic Or Clinical Uses

Treatment of hypertension to reduce elevated blood pressure.
Management of chronic stable angina pectoris by improving myocardial oxygen balance.
Treatment of variant (Prinzmetal) angina by preventing coronary artery spasm.
Off-label use in certain cases of Raynaud's phenomenon due to vasodilatory effects.
Adjunctive therapy in hypertrophic cardiomyopathy to reduce outflow obstruction.
Use in preterm labor to relax uterine smooth muscle (off-label).
Management of high-altitude pulmonary edema through pulmonary vasodilation (limited evidence).
Treatment of esophageal spasm as a smooth muscle relaxant.
Used cautiously in certain heart failure patients with concomitant hypertension.

Side Or Adverse Effects

Common headache and dizziness due to vasodilation and hypotension.
Flushing and warmth sensation from peripheral vasodilation.
Peripheral edema caused by precapillary arteriolar dilation.
Reflex tachycardia or palpitations, particularly with immediate-release forms.
Gingival hyperplasia in some patients with prolonged use.
Hypotension leading to syncope or lightheadedness.
Nausea, dyspepsia, and gastrointestinal discomfort.
Fatigue and weakness related to vasodilator effects.
Rare allergic reactions including rash and urticaria.
Worsening angina or myocardial ischemia due to rapid vasodilation.
Rare hepatic enzyme elevations indicating hepatotoxicity.
Exacerbation of gastroesophageal reflux symptoms.
Muscle cramps and tremors reported infrequently.
Cough, wheezing, or upper respiratory tract symptoms rarely observed.
Palpitations or atrial arrhythmias in sensitive patients.

Precautions

Use with caution in patients with severe coronary artery disease or recent myocardial infarction.
Monitor closely in patients with congestive heart failure due to risk of fluid retention.
Careful use in hepatic impairment due to altered metabolism and increased exposure.
Avoid sudden discontinuation to prevent rebound hypertension or exacerbation of angina.
Use cautiously in patients with aortic stenosis or other obstructive cardiac conditions.
Monitor blood pressure and heart rate regularly to detect hypotension or reflex tachycardia.
Consider lactose intolerance before prescribing extended-release formulations containing lactose.
Inform surgeons prior to surgery; medication may need to be stopped 36 hours before elective procedures.
Careful titration recommended in elderly patients to avoid excessive hypotension or falls.
Caution advised during pregnancy and breastfeeding due to limited safety data.
Avoid concomitant use with grapefruit products that may increase serum levels of nifedipine.
Assess drug interactions especially with CYP3A4 inhibitors and inducers.
Monitor for symptoms of worsening angina or cardiovascular status changes.
Educate patients about orthostatic hypotension and dizziness precautions.
Avoid use in gastrointestinal obstruction or malabsorption syndromes affecting drug uptake.

Warnings

Contraindicated in patients with severe coronary artery disease and unstable angina.
Avoid use within 2 weeks following acute myocardial infarction due to risk of cardiogenic shock.
Potential for severe hypotension and syncope; dose carefully adjusted.
Risk of exacerbated angina or myocardial ischemia with immediate-release nifedipine due to reflex tachycardia.
May cause excessive hypotension leading to falls especially in elderly or volume-depleted patients.
Avoid abrupt cessation to prevent rebound hypertension or cardiac events.
Use caution in patients with congestive heart failure; may aggravate symptoms.
Possibility of hepatic dysfunction necessitates monitoring liver enzymes.
Potential interaction with grapefruit juice increasing plasma nifedipine concentration dangerously.
Use in pregnancy only if clearly needed; possible fetal risks cannot be excluded.
Risk of drug accumulation in hepatic impairment leading to toxicity.
Extended-release preparations may cause tablet shell remnants in stool; clinically insignificant but should be explained to patients.
Not recommended for use in pediatric populations due to limited data and safety profile.
May cause dizziness and impair ability to operate machinery or drive.
Caution when used concomitantly with beta blockers to prevent excessive bradycardia or heart block.

Contraindication

Known hypersensitivity or allergy to nifedipine or other dihydropyridine calcium channel blockers.
Severe coronary artery disease especially unstable angina or recent myocardial infarction within 2 weeks.
Cardiogenic shock or systolic blood pressure markedly low.
Known severe hepatic impairment without appropriate dose adjustment.
Obstruction of gastrointestinal tract that impairs absorption of extended-release formulations.
Hypotension or marked bradycardia patients at baseline before treatment.
Patients with aortic stenosis with significant obstruction to outflow requiring caution.
Lactose intolerance in patients prescribed lactose-containing extended-release tablets may be contraindicated.
Concomitant use with strong CYP3A4 inhibitors where safer alternatives exist.
Pregnancy when benefits do not outweigh potential fetal risks.
Breastfeeding where risk to infant cannot be ruled out without close supervision.
Patients with multiple drug hypersensitivity syndromes related to the class.
Severe heart failure patients with preload-dependent cardiac output without cardiologist oversight.
Known intolerance or adverse reactions to similar calcium channel blocking agents.
Concomitant use with short-acting nifedipine formulations in certain high-risk patient groups.

Drug Interactions

Increased nifedipine levels with CYP3A4 inhibitors such as ketoconazole, erythromycin, clarithromycin, and grapefruit juice, leading to enhanced hypotensive effects.
Reduced efficacy when co-administered with CYP3A4 inducers like rifampin, phenytoin, carbamazepine, and St. John's Wort.
Additive hypotensive effects when used with other antihypertensives including beta-blockers, ACE inhibitors, and diuretics.
Potential for increased plasma concentrations when combined with protease inhibitors used in HIV therapy.
Interaction with cimetidine causing increased nifedipine plasma levels by inhibiting metabolism.
Co-administration with simvastatin may increase simvastatin exposure due to CYP3A4 inhibition.
Enhanced risk of bradycardia and heart block when combined with beta-blockers; dose adjustments required.
Additive vasodilatory effects with nitrates may cause profound hypotension.
Careful monitoring needed when combined with digoxin as either agent influences cardiac function.
Interaction potential with antidepressants such as SSRIs due to effects on CYP enzymes.
Co-administration with antifungals like itraconazole potentiates nifedipine effect via CYP3A4 inhibition.
Use with caution with other calcium channel blockers to avoid excessive cardiovascular depression.
Monitoring required when administered with immunosuppressants like cyclosporine due to shared metabolism.
Possible interaction with certain antiepileptics affecting nifedipine metabolism.
Concurrent use with alcohol may increase risk of hypotension and CNS side effects.

Preparations Of The Drug

Nifedipine extended-release tablets available in 30 mg, 60 mg, and 90 mg doses designed for once-daily administration.
Immediate-release tablets and capsules generally supplied in 10 mg and 20 mg doses for multiple daily dosing.
Combination products with other antihypertensives may be available but less common for nifedipine.
Extended-release formulations may include various brand-specific coatings affecting absorption.
Some tablets contain lactose as an inactive ingredient; relevant for patients with lactose intolerance.
Capsule formulations designed for rapid onset of action but limited by short half-life.
Extended-release formulations intended to provide stable plasma concentrations with reduced peak-trough variability.
Available as branded products including Adalat CC, Procardia XL, Nifedical XL, and generics with consistent bioequivalence.
Packaging includes blister packs or bottles with protective measures against moisture and light.
Oral route exclusively; no parenteral preparations widely available for outpatient use.
Supplementary patient information leaflets describing proper administration and storage conditions.
Available as prescription-only medications with dosing individualized based on clinical indications.